Skip to main content

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Status: closed to accrual

The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation

Inclusion Criteria

Able to understand the study requirements and provide written informed consent before any study assessment is performed
Male or female patients ≥ 18 to 65 years of age
Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor Key

Exclusion Criteria

Women of child-bearing potential, unless willing to comply with the use of highly effective methods of contraception as defined by the protocol
A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
Recipient with anti-HLA donor-specific antibody (DSA)

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.